Premium
Effects of Transcutaneous Application of Carbon Dioxide on diabetic muscle atrophy
Author(s) -
Kondo Hiroyo,
Tani Tomomi,
Naito Kana,
Niimi Yurina,
Nakane Moemi,
Sugiyama Yui,
Okayasu Kanako,
Takemoto Hatsumi,
Matsumoto Tomohiro,
Takuwa Miho,
Hirabayashi Takumi,
Ikeji Takuya,
Ono Kohei,
Fujino Hidemi
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.lb395
Subject(s) - muscle atrophy , atrophy , medicine , diabetes mellitus , endocrinology
Diabetes results in muscle atrophy, also called diabetic myopathy. Both the increase in muscle proteolysis and the decrease in muscle protein synthesis contribute to diabetic muscle atrophy. Transcutaneous application of carbon dioxide (CO 2 ) has been used for cardiac disease and skin problems for a long time. In addition, it has been reported the CO 2 treatment leads to an increase of muscle mass in normal rats. Therefore, the transcutaneous application of CO 2 would have a therapeutic potential for diabetic muscle atrophy. The aim of the present study was to investigate the effects of transcutaneous application of CO 2 on diabetic muscle atrophy. Methods Male Goto‐kakizaki rats were divided into control and CO 2 treatment groups. The hair on the lower limbs was shaved and the hydrogel was applied. The CO2 adaptor was attached to the limbs and sealed, and CO2 was administered into the adaptor for 30 min. This treatment was performed everyday for 8 weeks. Results The body weight, epididymal and retroperitoneal fat were lower in the CO 2 treatment group than in the control. In addition, the level of fasting blood glucose in the CO 2 treatment group was significantly decreased compared with the control. Furthermore, the muscle masses of lower limbs in the CO 2 treatment group were higher than those in the control. Conclution These results indicate that the transcutaneous CO 2 treatment may have a therapeutic potential for diabetic muscle atrophy. Support or Funding Information Supported by Grants‐in‐Aid for Science Research from the Japanese MEXT. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .